This site is intended for healthcare professionals

Phase III ECZTRA 6 trial of Adtralza meets its primary endpoints at 16 weeks for atopic dermatitis.- LEO Pharma

Read time: 1 mins
Last updated:20th Dec 2021
Published:23rd Oct 2021
LEO Pharma announced 16-week results of a 52-week monotherapy Phase III ECZTRA 6 trial showing Adtralza (tralokinumab) significantly improved primary and secondary measurements of efficacy among adolescents (aged 12 to 17) with moderate-to-severe atopic dermatitis.

The 16-week initial treatment period of the ECZTRA 6 trial (NCT03526861) assessed the efficacy and safety of tralokinumab 150 mg (n=98) or 300 mg (n=97) every two weeks (Q2W) compared to placebo (n=94) in adolescents. At week 16, tralokinumab met its primary and secondary endpoints, showing that significantly more patients treated with tralokinumab achieved a clinical response, compared to placebo, defined as achieving an IGA 0/1 and/or an EASI 751: 21.4% (p<0.001) of the tralokinumab 150 mg group and 17.5% (p="0.002)" of the tralokinumab 300 mg group achieved clear or almost-clear skin compared to 4.3% with placebo as measured by iga. in addition, 28.6% (p><0.001) of the tralokinumab 150 mg group and 27.8% (p="0.001)" of the tralokinumab 300 mg group achieved 75% or greater disease improvement from baseline compared to 6.4% with placebo as measured by easi.></0.001)></0.001)>

Secondary endpoints were all met, addressing extent and severity of atopic dermatitis (SCORAD), achieving at least a 4-point improvement in adolescent weekly average worst daily pruritus NRS score, and health-related quality of life related to dermatological conditions (CDLQI). The safety and tolerability of tralokinumab compared with placebo, when used to treat adolescents with moderate-to-severe atopic dermatitis, was also investigated. The overall frequency and severity of adverse events (AEs) in the trial were comparable across the treatment groups over 16 weeks (67% for tralokinumab 150 mg, 65% for tralokinumab 300 mg, and 62% for placebo). The week 16 results were shared during the 2021 Fall Clinical Dermatology Conference held virtually and with a hybrid option in Las Vegas.

Condition: Atopic Dermatitis (Eczema)
Type: drug

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.